Margarita I. Tikhaya

Margarita I. Tikhaya

Auto-generated profile, based on publicly available information

Margarita I. Tikhaya

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2019 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
NPNadezhda Podchernyaeva
Nadezhda Podchernyaeva
MKM.S. Konevina
M.S. Konevina
MTM.I. Tikhaya
M.I. Tikhaya
Облако Mail.Ru - это ваше персональное надежное хранилище в интернете. Все нужные файлы всегда под рукой, доступны в любой точке мира с компьютера или смартфона.

1 January 2023 in Voprosy detskoj dietologii
Verified
Journal Article
Closed access
ELE.V. Loshkova
E.V. Loshkova
EKElena Kondatyeva
Elena Kondatyeva
LKL.Ya. Klimov
L.Ya. Klimov
NPNadezhda Podchernyaeva
Nadezhda Podchernyaeva
NIN.A. Ilyenkova
N.A. Ilyenkova
AKAnatoly Khavkin
Anatoly Khavkin

14 October 2019 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
NPNadezhda Podchernyaeva
Nadezhda Podchernyaeva
MKM.S. Konevina
M.S. Konevina
MTM.I. Tikhaya
M.I. Tikhaya
Облако Mail.ru - это ваше персональное надежное хранилище в интернете.

30 July 2022 in Pediatrics. Consilium Medicum
Verified
Journal Article
Open access
PDF file
LGLelia A. Galstian
Lelia A. Galstian
MVMaksim V. Verbitsky
Maksim V. Verbitsky
APAngelina V. Polyanskaya
Angelina V. Polyanskaya
SCSvetlana N. Chebysheva
Svetlana N. Chebysheva
MKMariya A. Kudryashova
Mariya A. Kudryashova
КАКудряшова Мария Алексеевна
Кудряшова Мария Алексеевна
Uveitis associated with juvenile arthritis can be complicated by cataracts, retinal edema, and glaucoma, which carries a potential risk of disability in the child's organ of vision. Approximately 2540% of patients demonstrate insufficient effectiveness of the ongoing standard antirheumatic therapy, which requires the inclusion of genetically engineered biological therapy. According to the protocols, the drug of choice for juvenile arthritis associated with uveitis is adalimumab, which has shown high efficacy in many studies. However, some patients stop responding to therapy over time, which raises the question of switching to another genetically engineered biological drug (GЕBD). Our article presents a case of severe course with an early onset of juvenile idiopathic arthritis associated with uveitis. Due to the insufficient effectiveness of basic monotherapy with methorexate, as well as topical glucocorticoids, adilimumab was added to therapy a year after the onset of the disease. Over the next 5 years, the child was on this therapy with exacerbations of uveitis about 12 episodes per year. Subsequently, uveitis began to continuously recur, which raised the question of the development of probable resistance to adalimumab and the change of GEBD. The girl was switched to golimumab, which is a human monoclonal antibody that can bind to tumor necrosis factor-. This drug has been used for the treatment of juvenile idiopathic arthritis since 2017 for children weighing 40 kg and above, and after the completion of the multicenter GO-KIDS study, it is registered for children from 2 years of age. According to a number of studies, golimumab has shown its effectiveness in relation to the activity of uveitis in patients with arthritis, including those in childhood. In general, the issues of switching GEBD in cases of ineffective therapy with first-line drugs are a very urgent problem in pediatric rheumatology. In our case, switching to the GIBP golimumab resulted in a positive effect on the activity of rheumatoid uveitis and induction of remission of the articular syndrome.